Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

Hafsah Nabi, Bente Glintborg, AG Loft, O Hendricks, JK Pedersen, SA Just, Rabiah Ahmed, Kamilla Danebod, HL Munk, A Colic, A Linauskas, Dorte Vendelbo Jensen, LB Christensen, Natalia Manilo, N Lomborg, S Kristensen, F Mehnert, NS Krogh, Merete Lund Hetland

Original languageEnglish
Article numberOP16
Book seriesScandinavian Journal of Rheumatology, Supplement
Issue number130
Pages (from-to)14-5
Number of pages2
Publication statusPublished - 2021

Cite this